Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2

作者：Yuanchao Xie, Wanchao Yin, Yumin Zhang, Weijuan Shang, Zhen Wang, Xiaodong Luan, Guanghui Tian, Haji Akber Aisa, Yechun Xu, Gengfu Xiao, Jia Xuan Li, Hualiang Jiang, Shuyang Zhang, Leike Zhang, H. Eric Xu, Jingshan Shen · 发表于：Cell Research · 年份：2021 · DOI：10.1038/s41422-021-00570-1 · 被引用次数：135 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、PARP inhibition in cancer therapy

Since the declaration of COVID-19 as a global pandemic on March 11, 2020, this pandemic has been circulating for 17 months throughout the world, leading to more than 200 million infections and nearly 4.4 million deaths as of August 15, 2021. The pathogen of COVID-19 is a novel coronavirus named SARS-CoV-2, which shares ~79% genome sequence identity with SARS-CoV. 1 At the early stage of the COVID-19 outbreak, SARS-CoV-2 caused great panic in the hardest-hit areas due to its high transmissibility and pathogenicity. To fight the COVID-19 crisis, drug repurposing was immediately pursued in order to find potential therapeutics. Until now, though some treatment options are available, there still lack effective antiviral agents. Vaccination is considered as the best way to control this global pandemic, but the emerging SARS-CoV-2 variants pose a great challenge to the protective efficacy of the existing vaccines. Hence, in the long run, finding an effective antiviral medication against the SARS-CoV-2 infection is a pressing need.